Biological monitoring to assess dermal exposure to ethylene oxide vapours during an incidental release.

Autor: Boogaard PJ; Shell Health, Shell International B.V., P.O. Box 162, 2501 AN The Hague, The Netherlands. Electronic address: peter.boogaard@shell.com., van Puijvelde MJ; Shell Health, Shell International B.V., P.O. Box 162, 2501 AN The Hague, The Netherlands., Urbanus JH; Shell Health, Shell International B.V., P.O. Box 162, 2501 AN The Hague, The Netherlands.
Jazyk: angličtina
Zdroj: Toxicology letters [Toxicol Lett] 2014 Dec 15; Vol. 231 (3), pp. 387-90. Date of Electronic Publication: 2014 May 29.
DOI: 10.1016/j.toxlet.2014.05.014
Abstrakt: During a short incident in an ethylene oxide (EO) producing plant, EO vapour was released under high pressure. Operators wore full respiratory protection during repairs to fix the leak. To check the adequacy of the applied personal protective equipment and to address concerns about potential dermal exposure and subsequent uptake of EO, biological monitoring was applied by determination of the haemoglobin adducts of EO in blood. Based on the results of the biomonitoring, a risk assessment of dermal exposure to EO vapour was made. Calculations to estimate dermal exposure, based on two recently published models and using the relevant physical-chemical properties of EO, indicate that the dermal contribution to total exposure is expected to be negligible under normal operating circumstances. However, the models indicate that under accidental circumstances of product spillage, when high air concentrations can build up quickly and where incident response is conducted under respiratory protection with independently supplied air, the systemic exposure resulting from dermal absorption may reach levels of concern. The model estimates were compared to the actual biomonitoring data in the operators involved in the accidental release of EO vapour. The results suggest that when incidental exposures to high EO vapour concentrations (several thousand ppm) occur during periods in excess of 20-30 min, additional risk management measures, such as wearing chemical impervious suits, should be considered to control dermal uptake of EO.
(Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: